Skip to main content

Table 2 NSAID, glucocorticoid, and DMARD therapy in SpA with and without TB

From: Risk of tuberculosis in patients with spondyloarthritis: data from a centralized electronic database in Hong Kong

  SpA with TB SpA without TB P value
NSAIDs 43/43 (100.0%) 2783/2926 (95.1%) 0.14
glucocorticoid therapy > 6 months 6/43 (14.0%) 148/2926 (5.1%) 0.01
DMARDs 29/43 (67.4%) 1831/2926 (62.6%) 0.51
cDMARDs 21/43 (48.8%) 1609/2926 (55.0%) 0.42
sulfasalazine 16/43 (37.2%) 1253/2926 (42.8%) 0.46
methotrexate 9/43 (20.9%) 763/2926 (26.1%) 0.45
leflunomide 0/43 (0.0%) 156/2926 (5.3%) 0.12
bDMARDs 17/43 (39.5%) 709/2926 (24.2%) 0.02
TNFi 17/43 (39.5%) 666/2926 (22.8%) 0.001
infliximab 10/43 (23.3%) 98/2926 (3.3%) < 0.001
etanercept 2/43 (4.7%) 268/2926 (9.2%) 0.31
adalimumab 5/43 (11.6%) 235/2926 (8.0%) 0.39
golimumab 0/43 (0.0%) 196/2926 (6.7%) 0.08
certolizumab 0/43 (0.0%) 39/2926 (1.3%) 0.45
secukinumab 0/43 (0.0%) 69/2926 (2.4%) 0.31
ustekinumab 0/43 (0.0%) 19/2926 (0.6%) 0.60
  1. NSAID Non-steroidal anti-inflammatory drug; SpA Spondyloarthritis; TB Tuberculosis; DMARDs Disease modifying anti-rheumatic drugs; cDMARDs Conventional disease modifying antirheumatic drugs; bDMARDs Biologic disease modifying antirheumatic drugs; TNFi Tumour necrosis factor inhibitor